Biren Amin
Stock Analyst at Piper Sandler
(1.33)
# 3,414
Out of 4,858 analysts
57
Total ratings
40%
Success rate
-12.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $4.61 | +269.16% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.45 | +382.76% | 3 | May 14, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $110 → $70 | $37.81 | +85.14% | 7 | May 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $46 → $63 | $39.02 | +61.48% | 2 | Apr 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $30.06 | +69.66% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $12.47 | +204.73% | 1 | Mar 31, 2025 | |
| ELEV Elevation Oncology | Downgrades: Neutral | $10 → $0.7 | $0.38 | +84.45% | 2 | Mar 21, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $35.00 | +117.14% | 1 | Mar 19, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $2.45 | +390.80% | 1 | Feb 19, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $74 → $71 | $28.95 | +145.25% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $4 | $4.50 | -11.01% | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.02 | +288.03% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $9.48 | +121.52% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $66.18 | +73.77% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $19.30 | +65.85% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $5.16 | -41.86% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $8.82 | +70.07% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.48 | +4,629.73% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.46 | +10,972.51% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.97 | +708.08% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.67 | +1,173.41% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $4.36 | +11,367.89% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.95 | +135.49% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $518.60 | +33.24% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $2.83 | +253.98% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $23.54 | +329.06% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $124.17 | -44.43% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $452.44 | -65.74% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.73 | +7,761.27% | 4 | Mar 6, 2017 |
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $4.61
Upside: +269.16%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.45
Upside: +382.76%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $110 → $70
Current: $37.81
Upside: +85.14%
BridgeBio Pharma
Apr 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $39.02
Upside: +61.48%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $30.06
Upside: +69.66%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $12.47
Upside: +204.73%
Elevation Oncology
Mar 21, 2025
Downgrades: Neutral
Price Target: $10 → $0.7
Current: $0.38
Upside: +84.45%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $35.00
Upside: +117.14%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $2.45
Upside: +390.80%
Viking Therapeutics
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $28.95
Upside: +145.25%
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $4.50
Upside: -11.01%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $9.02
Upside: +288.03%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $9.48
Upside: +121.52%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $66.18
Upside: +73.77%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $19.30
Upside: +65.85%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $5.16
Upside: -41.86%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $8.82
Upside: +70.07%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.48
Upside: +4,629.73%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.46
Upside: +10,972.51%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $2.97
Upside: +708.08%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $2.67
Upside: +1,173.41%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $4.36
Upside: +11,367.89%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $5.95
Upside: +135.49%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $518.60
Upside: +33.24%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $2.83
Upside: +253.98%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $23.54
Upside: +329.06%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $124.17
Upside: -44.43%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $452.44
Upside: -65.74%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.73
Upside: +7,761.27%